Issue Date: July 31, 2017
Takeda taps Schrödinger for drug discovery
Takeda Pharmaceutical has entered a multitarget research collaboration with Schrödinger, a computational science firm. In an effort led by Schrödinger, the Japanese drug firm will provide protein crystal structures to guide the in silico design of new chemical entities in areas of therapeutic interest. Takeda has the option to license compounds from Schrödinger, paying up to $170 million per compound as well as royalties on future sales.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society